Understanding how certain cancer cells resist viral infections
NFkB-dependent antiviral pathways in VSV-resistant cancer cells
This study is looking at why some cancer cells can avoid getting infected by certain viruses that are used in cancer treatments, while healthy cells can fight off these infections, and it aims to find new ways to help treat cancer by understanding how these cells work.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rochester Institute of Technology NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-10209637 on NIH RePORTER |
What this research studies
This research investigates why some cancer cells can resist infections from oncolytic viruses like vesicular stomatitis virus (VSV), while normal cells can mount an immune response to prevent such infections. The study focuses on the role of NFκB, a protein that helps regulate immune responses, in these cancer cells. By examining different cancer cell lines, the researchers aim to identify the mechanisms that allow some tumors to maintain antiviral responses, which could lead to new treatment strategies. The approach includes in vitro experiments and modeling to explore how VSV interacts with these cancer cells.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with specific types of cancer that may exhibit resistance to viral infections.
Not a fit: Patients with cancers that do not exhibit antiviral responses or those who are not eligible for oncolytic virus therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that enhance the effectiveness of oncolytic viruses in treating certain cancers.
How similar studies have performed: Previous research has shown promising results in using oncolytic viruses for cancer treatment, indicating that this approach has potential for success.
Where this research is happening
Rochester, United States
- Rochester Institute of Technology — Rochester, United States (Active)
Researchers
- Principal investigator: Ferran, Maureen C — Rochester Institute of Technology
- Study coordinator: Ferran, Maureen C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.